Transient Elastography for the Detection of Liver Damage in Patients with HIV

详细信息    查看全文

• 作者：Abdurrahman Sagir ; Birgit Glaubach ; Kurtulus Sahin…
• 关键词：FibroScan庐 ; Hepatotoxicity ; Highly active antiretroviral therapy (HAART) ; HIV ; Liver ; Transient elastography
• 刊名：Infectious Diseases and Therapy
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：4
• 期：3
• 页码：355-364
• 全文大小：491 KB
• 参考文献：1.Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother. 2007;60:461鈥?.CrossRef PubMed
  2.Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27鈥?4.CrossRef PubMed
  3.Borrell C, Rodr铆guez-Sanz M, Pasar铆n MI, et al. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? Eur J Public Health. 2006;16:601鈥?.CrossRef PubMed
  4.Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS. 2008;3:653鈥?.CrossRef PubMed
  5.Cooper CL. HIV antiretroviral medications and hepatotoxicity. Curr Opin HIV AIDS. 2007;2:466鈥?3.CrossRef PubMed
  6.Chihrin S, Antoniou T, Raboud J, et al. Risk factors for grade 3鈥? liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy. AIDS Patient Care STDS. 2007;21:469鈥?8.CrossRef PubMed
  7.Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis. 2005;5:58.PubMed Central CrossRef PubMed
  8.Abrescia N, D鈥橝bbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des. 2005;11:3697鈥?10.CrossRef PubMed
  9.Kontorinis N. Dieterich D hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36鈥?3.PubMed
  10.Dore G. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management. J HIV Ther. 2003;8:96鈥?00.PubMed
  11.Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008;197:S279鈥?3.CrossRef PubMed
  12.N煤帽ez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44:S132鈥?.CrossRef PubMed
  13.Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol. 2009;15:2433鈥?0.PubMed Central CrossRef PubMed
  14.Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705鈥?3.CrossRef PubMed
  15.Erhardt A, Lorke J, Vogt C, et al. Transient elastography for diagnosing liver cirrhosis [in German]. Dtsch Med Wochenschr. 2006;131:2765鈥?.CrossRef PubMed
  16.Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343鈥?0.CrossRef PubMed
  17.Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403鈥?.PubMed Central CrossRef PubMed
  18.Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518鈥?6.CrossRef PubMed
  19.Gu茅chot J, Serfaty L, Bonnand AM, Chazouill猫res O, Poupon RE, Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol. 2000;32:447鈥?2.CrossRef PubMed
  20.Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867鈥?3.CrossRef PubMed
  21.McDonald H, Borinskya S, Kiryanov N, Gil A, Helander A, Leon DA. Comparative performance of biomarkers of alcohol consumption in a population sample of working-aged men in Russia: the Izhevsk Family Study. Addiction. 2013;108:1579鈥?9.PubMed Central CrossRef PubMed
  22.Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317鈥?5.CrossRef PubMed
  23.Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection. 2013;41:545鈥?1.CrossRef PubMed
  24.Prosperi MC, Fabbiani M, Fanti I, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012;12:296.PubMed Central CrossRef PubMed
  25.Casado JL. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine. AIDS Rev. 2013;15:139鈥?5.PubMed
  26.Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495鈥?00.CrossRef PubMed
  27.Mederacke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 2009;29:1500鈥?.CrossRef PubMed
  28.Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718鈥?3.CrossRef PubMed
  29.Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008;47:592鈥?.CrossRef PubMed
  30.Alkhouri N, Sedki E, Alisi A, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33:79鈥?5.CrossRef PubMed
  31.Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74鈥?0.CrossRef PubMed
  32.Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23鈥?1.CrossRef PubMed
  33.Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol. 2008;20:1194鈥?04.CrossRef PubMed
  34.Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis. 2006;38:363鈥?3.CrossRef PubMed
  35.Orenstein R, Tsogas N. Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection. Pharmacotherapy. 2002;22:1468鈥?8.CrossRef PubMed
  36.Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52鈥?0.PubMed
  
• 作者单位：Abdurrahman Sagir (1) (2)
  Birgit Glaubach (1)
  Kurtulus Sahin (3)
  Dirk Graf (1)
  Andreas Erhardt (1)
  Mark Oette (4)
  Dieter H盲ussinger (1)
  
  1. Klinik f眉r Gastroenterologie, Hepatologie und Infektiologie, Universit盲tsklinik D眉sseldorf, D眉sseldorf, Germany
  2. Bethesda Krankenhaus Duisburg, Duisburg, Germany
  3. Institut f眉r Medizinische Statistik, Informatik und Epidemiologie, Universit盲t zu K枚ln, Cologne, Germany
  4. Augustinerinnen Hospital, Cologne, Germany
  
• 刊物主题：Internal Medicine; Infectious Diseases;
• 出版者：Springer Healthcare
• ISSN：2193-6382

文摘

Introduction Highly active antiretroviral therapy (HAART) is effective and well tolerated, but hepatotoxicity is relatively common. Different non-invasive methods are available for detecting liver fibrosis in patients with chronic liver disease.